Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861326 | 0.70 | BRD4 (0.44) | CNR2MAPT | |
| SCHEMBL3449664 | 0.69 | MKNK1 (0.39) | CNR2FAAHCNR1ABHD12TNF | |
| SCHEMBL18584783 | 0.69 | CNR2 (0.57) | CNR2FAAHCNR1ABHD12MAPT | |
| SCHEMBL18584997 | 0.67 | CNR2 (0.43) | CNR2FAAHCNR1ABHD12 | |
| SCHEMBL3450711 | 0.65 | MAPT (0.42) | CNR2CNR1MAPT | |
| SCHEMBL19874000 | 0.63 | ALDH1A1 (0.34) | TNF | |
| SCHEMBL28652146 | 0.63 | CDK9 (0.40) | TNFMAPT | |
| SCHEMBL28227744 | 0.63 | BRD4 (0.43) | CNR2CNR1TNFMAPT | |
| SCHEMBL23121684 | 0.62 | TYR (0.40) | CNR2CNR1TNF | |
| SCHEMBL3450311 | 0.62 | GPR35 (0.37) | CNR2FAAHCNR1ABHD12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CNR2 517/4885FAAH 1978/4885CNR1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.